clinical trial · NCT05517421
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Immunovant Sciences GmbH·phase3·completed·n = 114
Thyroid Eye DiseaseBatoclimabPlacebo
brief summary
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
started
Nov 23, 2022
primary completion
Nov 2, 2025
completion
Nov 18, 2025
last updated
Dec 3, 2025
official title
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol